Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05053659 |
Title | Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma |
Recruitment | Recruiting |
Gender | both |
Phase | Phase I |
Variant Requirements | No |
Sponsors | Brian Hill, MD, PhD |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |
Facility | Status | City | State | Zip | Country | Details |
---|---|---|---|---|---|---|
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center | RECRUITING | Cleveland | Ohio | 44195 | United States | Details |